Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603069 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase 2 study of Parkinson's Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 13
- Study locations
NCT01603069: Completed Phase 2 study of Parkinson's Disease, sponsored by AstraZeneca.
NCT01603069 is a Phase 2 study of Parkinson's Disease that has completed, run by AstraZeneca. The registered enrollment target is 51 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (92% lower). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01603069, a Phase 2 study of Parkinson's Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a study where AZD3241 or placebo is given to patients with Parkinson's disease in a blinded and randomized assignment. The main objective is to see if safety and tolerability of the drug is acceptable.
Primary Outcome
Vital signs: systolic and diastolic blood pressure and pulse including orthostatic challenge will be assessed. Change from baseline at each visit will be calculated as the visit value minus the baseline value for each vital sign: Blood Pressure, pulse rate (supine and standing), weight and oral temperature.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD3241 300 mg BID
- DRUG AZD3241 600 mg BID
Study Locations (13)
Florida
- Research Site - Atlantis
- Research Site - Boca Raton
- Research Site - Orlando
- Research Site - Sunrise
- Research Site - Tampa
New Jersey
- Research Site - Lawrenceville
- Research Site - Marlton
Alabama
- Research Site - Birmingham
California
- Research Site - Long Beach
Connecticut
- Research Site - New Haven
Kansas
- Research Site - Kansas City
Michigan
- Research Site - Bingham Farms
Nebraska
- Research Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT01603069 record still lists
NCT01603069 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01603069 lists 13 locations in 8 states (Florida, New Jersey, Alabama).
Frequently Asked Questions
What is clinical trial NCT01603069 about?
NCT01603069 is a clinical study titled "A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease". This is a study where AZD3241 or placebo is given to patients with Parkinson's disease in a blinded and randomized assignment. The main objective is to see if safety and tolerability of the drug is acceptable.
What is the current status of trial NCT01603069?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2012-10. Estimated completion is 2013-06.
What conditions does trial NCT01603069 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT01603069?
The interventions under investigation include: Placebo (DRUG), AZD3241 300 mg BID (DRUG), AZD3241 600 mg BID (DRUG).
Who is sponsoring clinical trial NCT01603069?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01603069 being conducted?
This trial has 13 study locations across Alabama, California, Connecticut, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01603069's enrollment target sits among peer trials
51 80th of 158 higher than 78 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia